Ajanta Pharma Limited (NSE:AJANTPHARM)
2,695.20
-56.20 (-2.04%)
Aug 1, 2025, 3:29 PM IST
Ajanta Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
48,058 | 46,481 | 42,087 | 37,426 | 33,410 | 28,897 | Upgrade | |
Revenue Growth (YoY) | 10.92% | 10.44% | 12.45% | 12.02% | 15.62% | 11.66% | Upgrade |
Cost of Revenue | 11,509 | 11,429 | 11,210 | 11,102 | 8,840 | 6,832 | Upgrade |
Gross Profit | 36,549 | 35,052 | 30,877 | 26,324 | 24,570 | 22,065 | Upgrade |
Selling, General & Admin | 11,239 | 11,048 | 9,122 | 7,978 | 6,571 | 5,523 | Upgrade |
Other Operating Expenses | 12,123 | 11,279 | 9,944 | 10,241 | 8,667 | 6,478 | Upgrade |
Operating Expenses | 24,876 | 23,768 | 20,420 | 19,527 | 16,491 | 13,162 | Upgrade |
Operating Income | 11,673 | 11,285 | 10,457 | 6,798 | 8,079 | 8,903 | Upgrade |
Interest Expense | -252.6 | -207.3 | -72.1 | -58.4 | -102 | -82.7 | Upgrade |
Interest & Investment Income | 471.6 | 471.6 | 277.1 | 84.6 | 146.5 | 35.1 | Upgrade |
Currency Exchange Gain (Loss) | 41.8 | 282.1 | 158.7 | 660.7 | 563.7 | 45.1 | Upgrade |
Other Non Operating Income (Expenses) | 28.8 | 41.4 | 264.1 | 61.5 | 323.8 | 40.9 | Upgrade |
EBT Excluding Unusual Items | 11,963 | 11,872 | 11,084 | 7,546 | 9,011 | 8,941 | Upgrade |
Gain (Loss) on Sale of Investments | 25.2 | 25.2 | 20.1 | -40 | 122.8 | 82.7 | Upgrade |
Gain (Loss) on Sale of Assets | -6 | -6 | 34.9 | -53.5 | -38.7 | -22.1 | Upgrade |
Pretax Income | 11,982 | 11,892 | 11,139 | 7,453 | 9,095 | 9,002 | Upgrade |
Income Tax Expense | 2,682 | 2,688 | 2,978 | 1,573 | 1,968 | 2,463 | Upgrade |
Net Income | 9,300 | 9,204 | 8,162 | 5,880 | 7,127 | 6,539 | Upgrade |
Net Income to Common | 9,300 | 9,204 | 8,162 | 5,880 | 7,127 | 6,539 | Upgrade |
Net Income Growth | 8.92% | 12.77% | 38.81% | -17.50% | 8.99% | 39.80% | Upgrade |
Shares Outstanding (Basic) | 125 | 125 | 126 | 128 | 130 | 131 | Upgrade |
Shares Outstanding (Diluted) | 125 | 125 | 126 | 128 | 130 | 131 | Upgrade |
Shares Change (YoY) | -0.82% | -0.66% | -1.65% | -1.19% | -0.74% | -0.21% | Upgrade |
EPS (Basic) | 74.45 | 73.56 | 64.82 | 45.89 | 54.97 | 50.06 | Upgrade |
EPS (Diluted) | 74.42 | 73.53 | 64.77 | 45.89 | 54.96 | 50.06 | Upgrade |
EPS Growth | 9.82% | 13.53% | 41.14% | -16.50% | 9.79% | 40.09% | Upgrade |
Free Cash Flow | - | 8,393 | 6,327 | 6,176 | 4,129 | 4,047 | Upgrade |
Free Cash Flow Per Share | - | 67.05 | 50.21 | 48.20 | 31.84 | 30.98 | Upgrade |
Dividend Per Share | 28.000 | 28.000 | 36.000 | 7.000 | 6.333 | 6.333 | Upgrade |
Dividend Growth | 7.69% | -22.22% | 414.29% | 10.53% | - | -26.92% | Upgrade |
Gross Margin | 76.05% | 75.41% | 73.36% | 70.34% | 73.54% | 76.36% | Upgrade |
Operating Margin | 24.29% | 24.28% | 24.84% | 18.16% | 24.18% | 30.81% | Upgrade |
Profit Margin | 19.35% | 19.80% | 19.39% | 15.71% | 21.33% | 22.63% | Upgrade |
Free Cash Flow Margin | - | 18.06% | 15.03% | 16.50% | 12.36% | 14.01% | Upgrade |
EBITDA | 12,925 | 12,522 | 11,638 | 7,952 | 9,173 | 9,889 | Upgrade |
EBITDA Margin | 26.89% | 26.94% | 27.65% | 21.25% | 27.46% | 34.22% | Upgrade |
D&A For EBITDA | 1,252 | 1,238 | 1,181 | 1,154 | 1,094 | 985.9 | Upgrade |
EBIT | 11,673 | 11,285 | 10,457 | 6,798 | 8,079 | 8,903 | Upgrade |
EBIT Margin | 24.29% | 24.28% | 24.84% | 18.16% | 24.18% | 30.81% | Upgrade |
Effective Tax Rate | 22.38% | 22.60% | 26.73% | 21.10% | 21.64% | 27.36% | Upgrade |
Revenue as Reported | 49,002 | 47,426 | 42,933 | 38,413 | 34,567 | 29,157 | Upgrade |
Advertising Expenses | - | 57.6 | 44.9 | 50.2 | 47.8 | 16.2 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.